X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Recent Posts

Medicare Monday: A closer look at Medicare Part B

By Kelsey Lang  |    January 16, 2017
We took a deeper dive on Medicare Part D last week, so today we’re switching gears and talking about Medicare Part B.   Read More

Medicare Monday: New research finds trends in Average Sales Price of Part B drugs remains stable

By Kelsey Lang  |    December 19, 2016
Earlier this year, we looked at Average Sales Price (ASP) and how it works in Medicare Part B. As you may remember, ASP (the method for reimbursing drugs covered by Part B) is a market-based price...   Read More

Medicare Monday: How existing CMMI models affect Medicare Part B

By Kelsey Lang  |    November 7, 2016
Earlier this year the Center for Medicare & Medicaid Innovation (CMMI) proposed the Medicare Part B Drug Payment Model, also known as the Part B Demo, an experiment that would change how providers...   Read More

New Report: Part B proposal is more aggressive than previous efforts

By Kelsey Lang  |    June 1, 2016
In the more than 1,300 comments submitted to the Centers for Medicare & Medicaid Services (CMS) on the Part B Drug Payment Model, a wide range of organizations raised concern with the...   Read More

Medicare Monday: Part B proposal lacks essential patient protections

By Kelsey Lang  |    May 2, 2016
We’ve highlighted how the proposed Part B model lacks safeguards to protect patients from barriers and reduced quality of care. Some stakeholders have suggested that the Part B proposal looks a...   Read More

New Research: Access and quality implications of CMS proposed Part B model

By Kelsey Lang  |    April 27, 2016
In recent weeks, providers and stakeholders across the health care system have raised concerns that the Part B Drug Payment Model proposed by the Centers for Medicare & Medicaid Services (CMS) lacks...   Read More

Medicare Monday: Provider consolidation drives up costs for patients and government

By Kelsey Lang  |    April 18, 2016
Two recent studies add to a growing body of research on how consolidation is driving up treatment costs. More and more cancer treatments are being administered at hospital outpatient facilities...   Read More

ICYMI: American Society for Clinical Oncology statement on clinical pathways

By Kelsey Lang  |    January 18, 2016
Last week, the American Society for Clinical Oncology (ASCO) issued a policy statement calling for improvements in clinical pathway programs. The statement responds to the growing concern that...   Read More

Medicare Monday: Part B and biosimilars, part 2

By Kelsey Lang  |    November 30, 2015
Earlier this month, Medicare Monday covered the Center for Medicare & Medicaid Services (CMS) final rule on reimbursement for biosimilars and the implications of using a single billing code to...   Read More

Medicare Monday: New research finds drugs not a key driver of Medicare Part B costs

By Kelsey Lang  |    October 26, 2015
Over the last several weeks, Medicare Monday has talked about services covered by Medicare Part B and average sales price (ASP), the method for reimbursing drugs covered by Part B.  In particular,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates